News – Page 1109 – Endpoints News

Aileron Therapeutics files for a $69M IPO as new offerings heat up

8 years ago

Moving on from a trial disaster, Juno reports positive data for JCAR017 -- and a death

8 years ago

With one BLA at the FDA, Kite hustles along impressive new leukemia data and sounds a note of caution on safety

8 years ago

Roche’s ‘success’ with its big Perjeta/Herceptin PhIII falls flat at ASCO, but it’s a boost for Puma

8 years ago

Innate Pharma moves on from a trial disaster with a €40M in-licensing pact with Novo Nordisk

8 years ago

Regeneron, Sanofi make their case for another PD-1 drug — and they’re not settling for sixth place

8 years ago

Nanjing Legend wows ASCO researchers with early data on a BCMA-targeted CAR-T contender

8 years ago

Bluebird has a promising new update on its BCMA CAR-T for multiple myeloma, but is it still the leader?

8 years ago

PD-L1 checkpoint player Merck KGaA dives into next-gen work with F-star collaboration

8 years ago

AstraZeneca’s PARP drug Lynparza easily outscores chemo in PhIII breast cancer study

8 years ago

J&J’s stellar prostate cancer data signals the likelihood of a broader market approval, as Pfizer rival struggles

8 years ago

Incyte keeps the ASCO spotlight focused on its closely-watched IDO1 drug epacadostat

8 years ago

A LAG-3, Opdivo combo from Bristol-Myers offers a proof-of-concept glimpse of limited success

8 years ago

Loxo takes center stage at ASCO with its groundbreaking shot at a biomarker-based cancer drug approval

8 years ago

Minerva shares jump as J&J hands over $30M, revises insomnia drug pact; Iroko lays off 122

8 years ago

Eli Lilly's CFO retiring after 27 years at company; Alexion names a new slate of execs

8 years ago

Thumbs up: Cancer drug R&D is exploding, get ready for the pricing debate to follow

8 years ago

Takeda-backed Mersana joins the biotech IPO queue with a $75M offering and ambitious plans for ADC tech

8 years ago

Endocyte slashes staff and retrenches in the wake of back-to-back R&D setbacks

8 years ago

Bristol-Myers and Seattle Genetics move a promising flagship combo into PhIII

8 years ago

Alexion’s new CEO is bringing an old colleague in to run R&D, can new deals be far behind?

8 years ago

Checkpoint combos for cancer are all the rage as trial sponsors line up hundreds of new studies — report

8 years ago

ViiV, GSK gamble a surprise $130M chip in a high-stakes HIV playoff with Gilead

8 years ago

Ben-Gurion University seeking partner to repurpose old lymphoma drug to treat ALS

8 years ago

First page Previous page 1106 1107 110811091110 1111 1112 Next page Last page